Clinical Trial Update: Neoadjuvant L19IL2/L19TNF- Pivotal Study [Phase 3]

View source ↗

Summary

Phase 3 pivotal neoadjuvant trial of L19IL2/L19TNF for malignant melanoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• L19IL2/L19TNF

Snippet

Sponsor: Philogen S.p.A. | Conditions: Malignant Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING